Research programme: cancer therapeutics - Exelixis

Drug Profile

Research programme: cancer therapeutics - Exelixis

Alternative Names: XL541

Latest Information Update: 09 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Class
  • Mechanism of Action Cyclin dependent kinase 9 inhibitors; MTOR protein inhibitors; Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Sphingosine-1-phosphate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Feb 2011 Research programme: cancer therapeutics - Exelixis is available for licensing as of 22 Feb 2011.
  • 22 Feb 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 18 Dec 2008 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top